Callan Family Office’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.5M | Buy |
35,000
+16,487
| +89% | +$3.06M | 0.21% | 117 |
|
|
2025
Q1 | $3.88M | Sell |
18,513
-2,592
| -12% | -$543K | 0.29% | 77 |
|
|
2024
Q4 | $3.75M | Buy |
21,105
+17,886
| +556% | +$3.18M | 0.24% | 79 |
|
|
2024
Q3 | $636K | Buy |
3,219
+106
| +3% | +$20.9K | 0.11% | 92 |
|
|
2024
Q2 | $534K | Buy |
3,113
+729
| +31% | +$125K | 0.1% | 80 |
|
|
2024
Q1 | $434K | Sell |
2,384
-114
| -5% | -$20.8K | 0.1% | 61 |
|
|
2023
Q4 | $387K | Buy |
2,498
+114
| +5% | +$17.7K | 0.1% | 65 |
|
|
2023
Q3 | $355K | Sell |
2,384
-690
| -22% | -$103K | 0.09% | 64 |
|
|
2023
Q2 | $414K | Sell |
3,074
-425
| -12% | -$57.3K | 0.11% | 69 |
|
|
2023
Q1 | $558K | Buy |
3,499
+1,487
| +74% | +$237K | 0.14% | 89 |
|
|
2022
Q4 | $325K | Buy |
+2,012
| New | +$325K | 0.1% | 78 |
|